BiotechTube

Avacincaptad Pegol + Avastin + Lucentis + Eylea

Phase 2Terminated
0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neovascular Age-Related Macular Degeneration

Conditions

Neovascular Age-Related Macular Degeneration

Trial Timeline

Oct 20, 2016 → Apr 24, 2018

NCT ID
NCT05571267

About Avacincaptad Pegol + Avastin + Lucentis + Eylea

Avacincaptad Pegol + Avastin + Lucentis + Eylea is a phase 2 stage product being developed by Astellas Pharma for Neovascular Age-Related Macular Degeneration. The current trial status is terminated. This product is registered under clinical trial identifier NCT05571267. Target conditions include Neovascular Age-Related Macular Degeneration.

What happened to similar drugs?

18 of 20 similar drugs in Neovascular Age-Related Macular Degeneration were approved

Approved (18) Terminated (3) Active (2)
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intraviteal Ranibizumab 0.5mgNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅BrolucizumabNovartisApproved

Hype Score Breakdown

Clinical
12
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05571267Phase 2Terminated

Competing Products

20 competing products in Neovascular Age-Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
39
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
47
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
39
LucentisNovartisPre-clinical
26
ranibizumabNovartisPhase 3
40
BrolucizumabNovartisPre-clinical
18
ranibizumabNovartisApproved
43
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
26
BeovuNovartisPre-clinical
26
RanibizumabNovartisPhase 3
40
RanibizumabNovartisApproved
43
Intraviteal Ranibizumab 0.5mgNovartisApproved
43
RanibizumabNovartisApproved
43